Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter

References

• Gage KL, Burkot TR, Eisen RJ, Hayes EB. Climate and vectorborne diseases. Am J Prev Med 2008; 35:436 - 50; http://dx.doi.org/10.1016/j.amepre.2008.08.030; PMID: 18929970
   PubMed Web of Science ®Google Scholar
• Semenza JC, Menne B. Climate change and infectious diseases in Europe. Lancet Infect Dis 2009; 9:365 - 75; http://dx.doi.org/10.1016/S1473-3099(09)70104-5; PMID: 19467476
   PubMed Web of Science ®Google Scholar
• WHO. Severe acute respiratory syndrome (SARS): Status of the outbreak and lessons for the immediate future. 2003. Available from: http://www.who.int/csr/don/2003_04_11/en/
   Google Scholar
• Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, et al, KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369:407 - 16; http://dx.doi.org/10.1056/NEJMoa1306742; PMID: 23782161
   PubMed Web of Science ®Google Scholar
• WHO. Evolution of a pandemic A(H1N1) 2009. 2013.
   Google Scholar
• Xiong X, Martin SR, Haire LF, Wharton SA, Daniels RS, Bennett MS, McCauley JW, Collins PJ, Walker PA, Skehel JJ, et al. Receptor binding by an H7N9 influenza virus from humans. Nature 2013; 499:496 - 9; http://dx.doi.org/10.1038/nature12372; PMID: 23787694
   PubMed Web of Science ®Google Scholar
• WHO. Table of Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2013. 2013. Available from: http://www.who.int/influenza/human_animal_interface/EN_GIP_20131008CumulativeNumberH5N1cases.pdf
   Google Scholar
• Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010; 29:806 - 11; http://dx.doi.org/10.1097/INF.0b013e3181e2872f; PMID: 20458256
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Orsi A, de Florentiis D, Parodi V, Rappazzo E, Coppelli M, Durando P, Icardi G. Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60: Evaluation of immunogenicity, cross-protection, safety and tolerability. Hum Vaccin Immunother 2013; 9; In press http://dx.doi.org/10.4161/hv.23240; PMID: 23295262
   PubMed Web of Science ®Google Scholar
• Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365:1406 - 16; http://dx.doi.org/10.1056/NEJMoa1010331; PMID: 21995388
   PubMed Web of Science ®Google Scholar
• Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733 - 9; http://dx.doi.org/10.1016/j.vaccine.2011.07.128; PMID: 21835220
   PubMed Web of Science ®Google Scholar
• Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767 - 77; http://dx.doi.org/10.1017/S0022172400022610; PMID: 4509641
   PubMedGoogle Scholar
• de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115:63 - 73; PMID: 15088777
   PubMedGoogle Scholar
• Treanor J, Wright PF. Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) 2003; 115:97 - 104; PMID: 15088780
   PubMedGoogle Scholar
• Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24:157 - 60; PMID: 3722363
   PubMed Web of Science ®Google Scholar
• Stephenson I, Wood JM, Nicholson KG, Zambon MC. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 2003; 70:391 - 8; http://dx.doi.org/10.1002/jmv.10408; PMID: 12767002
   PubMed Web of Science ®Google Scholar
• Monto AS, Maassab HF. Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. J Clin Microbiol 1981; 13:54 - 7; PMID: 7462419
   PubMed Web of Science ®Google Scholar
• Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011; 30:1081 - 5; http://dx.doi.org/10.1097/INF.0b013e3182367662; PMID: 21983214
   PubMed Web of Science ®Google Scholar
• Granström M, Voordouw AC. Registration of influenza vaccines for children in Europe. Vaccine 2011; 29:7572 - 5; http://dx.doi.org/10.1016/j.vaccine.2011.08.017; PMID: 21820474
   PubMed Web of Science ®Google Scholar
• Eichelberger M, Golding H, Hess M, Weir J, Subbarao K, Luke CJ, Friede M, Wood D. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 2008; 26:4299 - 303; http://dx.doi.org/10.1016/j.vaccine.2008.06.012; PMID: 18582523
   PubMed Web of Science ®Google Scholar
• Haaheim LR, Katz JM. Immune correlates of protection against influenza: challenges for licensure of seasonal and pandemic influenza vaccines, Miami, FL, USA, March 1-3, 2010. Influenza Other Respir Viruses 2011; 5:288 - 95; http://dx.doi.org/10.1111/j.1750-2659.2011.00242.x; PMID: 21651740
   PubMedGoogle Scholar
• Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008; 15:1042 - 53; http://dx.doi.org/10.1128/CVI.00397-07; PMID: 18448618
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006; 176:10 6333 - 9
   PubMed Web of Science ®Google Scholar
• McElhaney JE. Influenza vaccine responses in older adults. Ageing Res Rev 2011; 10:379 - 88; http://dx.doi.org/10.1016/j.arr.2010.10.008; PMID: 21055484
   PubMed Web of Science ®Google Scholar
• Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res 2011; 162:19 - 30; http://dx.doi.org/10.1016/j.virusres.2011.09.022; PMID: 21963677
   PubMed Web of Science ®Google Scholar
• McCullers JA, Huber VC. Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother 2012; 8:34 - 44; http://dx.doi.org/10.4161/hv.8.1.18214; PMID: 22252001
   PubMed Web of Science ®Google Scholar
• Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother 2012; 8:45 - 58; http://dx.doi.org/10.4161/hv.8.1.18859; PMID: 22251994
   PubMed Web of Science ®Google Scholar
• Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010; 363:2036 - 44; http://dx.doi.org/10.1056/NEJMra1002842; PMID: 21083388
   PubMed Web of Science ®Google Scholar
• Shaw A. New technologies for new influenza vaccines. Vaccine 2012; 30:4927 - 33; http://dx.doi.org/10.1016/j.vaccine.2012.04.095; PMID: 22579861
   PubMed Web of Science ®Google Scholar
• WHO. Table for pandemic and potentially pandemic influenza vaccines. 2013. Available from: http://www.who.int/entity/immunization/research/development/Table_pandemic_vaccines.xls?ua=1
   Google Scholar
• Amorij JP, Hinrichs WLj, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect Dis 2010; 10:699 - 711; http://dx.doi.org/10.1016/S1473-3099(10)70157-2; PMID: 20883966
   PubMed Web of Science ®Google Scholar
• Palese P. Making better influenza virus vaccines?. Emerg Infect Dis 2006; 12:61 - 5; http://dx.doi.org/10.3201/eid1201.051043; PMID: 16494719
   PubMed Web of Science ®Google Scholar
• Monto AS, Ohmit SE. Seasonal influenza vaccines: evolutions and future trends. Expert Rev Vaccines 2009; 8:383 - 9; http://dx.doi.org/10.1586/erv.09.9; PMID: 19348555
   PubMed Web of Science ®Google Scholar
• Gilbert SC. Advances in the development of universal influenza vaccines. Influenza Other Respi Viruses 2013; 7:5 750 - 8; http://dx.doi.org/10.1111/irv.12013; PMID: 22998622
   PubMed Web of Science ®Google Scholar
• Rudolph W, Ben Yedidia T. A universal influenza vaccine: where are we in the pursuit of this “Holy Grail”?. Hum Vaccin 2011; 7:10 - 1; http://dx.doi.org/10.4161/hv.7.1.14925; PMID: 21285533
   PubMed Web of Science ®Google Scholar
• Safdar A, Cox MM. Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin Investig Drugs 2007; 16:927 - 34; http://dx.doi.org/10.1517/13543784.16.7.927; PMID: 17594180
   PubMed Web of Science ®Google Scholar
• Hillaire ML, Osterhaus AD, Rimmelzwaan GF. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011; 2011:939860
   PubMedGoogle Scholar
• Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009; 8:499 - 508; http://dx.doi.org/10.1586/erv.09.6; PMID: 19348565
   PubMed Web of Science ®Google Scholar
• The First WHO integrated meeting on development and clinical trials of Influenza vaccines that induce broadly protective and long-lasting immune responses. 2013. Available from: http://www.who.int/immunization/research/meetings_workshops/fluvaccines_devclinicaltrials_jan13/en/
   Google Scholar
• Van Kerkhove MD, Broberg E, Engelhardt OG, Wood J, Nicoll A, CONSISE steering committee. The consortium for the standardization of influenza seroepidemiology (CONSISE): a global partnership to standardize influenza seroepidemiology and develop influenza investigation protocols to inform public health policy. Influenza Other Respir Viruses 2013; 7:231 - 4; http://dx.doi.org/10.1111/irv.12068; PMID: 23280042
   PubMed Web of Science ®Google Scholar
• Wagner R, Pfleiderer M. Reproducibility of assays for influenza vaccine immunogenicity determination: progress towards consistency. Expert Rev Vaccines 2012; 11:881 - 3; http://dx.doi.org/10.1586/erv.12.62; PMID: 23002967
   PubMed Web of Science ®Google Scholar
• Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 2013; 12:519 - 36; http://dx.doi.org/10.1586/erv.13.35; PMID: 23659300
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 2008; 26:Suppl 4 D41 - 4; http://dx.doi.org/10.1016/j.vaccine.2008.07.043; PMID: 19230158
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47:3 401 - 9
   PubMed Web of Science ®Google Scholar
• Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181:1133 - 7; http://dx.doi.org/10.1086/315323; PMID: 10720541
   PubMed Web of Science ®Google Scholar
• Laidlaw BJ, Decman V, Ali MA, Abt MC, Wolf AI, Monticelli LA, Mozdzanowska K, Angelosanto JM, Artis D, Erikson J, et al. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog 2013; 9:e1003207; http://dx.doi.org/10.1371/journal.ppat.1003207; PMID: 23516357
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246 - 51; http://dx.doi.org/10.1126/science.1171491; PMID: 19251591
   PubMed Web of Science ®Google Scholar
• Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008; 3:e3942; http://dx.doi.org/10.1371/journal.pone.0003942; PMID: 19079604
   PubMed Web of Science ®Google Scholar
• Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265 - 73; http://dx.doi.org/10.1038/nsmb.1566; PMID: 19234466
   PubMed Web of Science ®Google Scholar
• Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, et al. Highly conserved protective epitopes on influenza B viruses. Science 2012; 337:1343 - 8; http://dx.doi.org/10.1126/science.1222908; PMID: 22878502
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, et al, VRC 306 Study Team. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916 - 24; http://dx.doi.org/10.1016/S1473-3099(11)70240-7; PMID: 21975270
   PubMed Web of Science ®Google Scholar
• Bommakanti G, Lu X, Citron MP, Najar TA, Heidecker GJ, ter Meulen J, Varadarajan R, Liang X. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 2012; 86:13434 - 44; http://dx.doi.org/10.1128/JVI.01429-12; PMID: 23015722
   PubMed Web of Science ®Google Scholar
• Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010; 1:1; http://dx.doi.org/10.1128/mBio.00018-10; PMID: 20689752
   PubMed Web of Science ®Google Scholar
• Krammer F, Pica N, Hai R, Margine I, Palese P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 2013; 87:6542 - 50; http://dx.doi.org/10.1128/JVI.00641-13; PMID: 23576508
   PubMed Web of Science ®Google Scholar
• Corti D, Suguitan AL Jr., Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120:1663 - 73; http://dx.doi.org/10.1172/JCI41902; PMID: 20389023
   PubMed Web of Science ®Google Scholar
• Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972; 286:1329 - 32; http://dx.doi.org/10.1056/NEJM197206222862502; PMID: 5027388
   PubMed Web of Science ®Google Scholar
• Couch RB, Atmar RL, Keitel WA, Quarles JM, Wells J, Arden N, Niño D. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 2012; 31:190 - 5; http://dx.doi.org/10.1016/j.vaccine.2012.10.065; PMID: 23107591
   PubMed Web of Science ®Google Scholar
• Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4:e59; http://dx.doi.org/10.1371/journal.pmed.0040059; PMID: 17298168
   PubMed Web of Science ®Google Scholar
• Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973; 1:7804 623 - 5; http://dx.doi.org/10.1016/S0140-6736(73)92196-X; PMID: 4121842
   PubMed Web of Science ®Google Scholar
• Pushko P, Kort T, Nathan M, Pearce MB, Smith G, Tumpey TM. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 2010; 28:4771 - 6; http://dx.doi.org/10.1016/j.vaccine.2010.04.093; PMID: 20470801
   PubMed Web of Science ®Google Scholar
• Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, Niño D, Belmont JW. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 2013; 207:974 - 81; http://dx.doi.org/10.1093/infdis/jis935; PMID: 23307936
   PubMed Web of Science ®Google Scholar
• Lambré CR, Terzidis H, Greffard A, Webster RG. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 1990; 135:49 - 57; http://dx.doi.org/10.1016/0022-1759(90)90255-T; PMID: 1703190
   PubMed Web of Science ®Google Scholar
• Cate TR, Rayford Y, Niño D, Winokur P, Brady R, Belshe R, Chen W, Atmar RL, Couch RB. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28:2076 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.12.041; PMID: 20044052
   PubMed Web of Science ®Google Scholar
• Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Xu KW, Lorbetskie B, Gingras G, Aubin Y, Van Domselaar G, et al. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 2010; 28:5774 - 84; http://dx.doi.org/10.1016/j.vaccine.2010.06.075; PMID: 20621113
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Scientific workshop on serology assays and correlates of protection for influenza vaccines. 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/12/WC500100205.pdf
   Google Scholar
• Gavrilov V, Orekov T, Alabanza C, Porika U, Jiang H, Connolly K, Pincus S. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay. J Virol Methods 2011; 173:364 - 73; http://dx.doi.org/10.1016/j.jviromet.2011.03.011; PMID: 21419169
   PubMed Web of Science ®Google Scholar
• Hassantoufighi A, Zhang H, Sandbulte M, Gao J, Manischewitz J, King L, Golding H, Straight TM, Eichelberger MC. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 2010; 28:790 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.10.066; PMID: 19887135
   PubMed Web of Science ®Google Scholar
• El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X.. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011; 186:2 1022 - 31
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004; 172:9 5598 - 605
   PubMed Web of Science ®Google Scholar
• Shaw AR. Universal influenza vaccine: the holy grail?. Expert Rev Vaccines 2012; 11:923 - 7; http://dx.doi.org/10.1586/erv.12.73; PMID: 23002973
   PubMed Web of Science ®Google Scholar
• Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009; 27:1440 - 7; http://dx.doi.org/10.1016/j.vaccine.2008.12.034; PMID: 19146898
   PubMed Web of Science ®Google Scholar
• Livingston BD, Higgins D, Van Nest G. Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs 2006; 20:6 335 - 40
   PubMed Web of Science ®Google Scholar
• Zhong W, He J, Tang X, Liu F, Lu X, Zeng H, Vafai A, Fu TM, Katz JM, Hancock K. Development and evaluation of an M2-293FT cell-based flow cytometric assay for quantification of antibody response to native form of matrix protein 2 of influenza A viruses. J Immunol Methods 2011; 369:115 - 24; http://dx.doi.org/10.1016/j.jim.2011.04.010; PMID: 21570401
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13 - 7; http://dx.doi.org/10.1056/NEJM198307073090103; PMID: 6602294
   PubMed Web of Science ®Google Scholar
• Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, Vita R, Ponomarenko J, Scheuermann RH, Sette A, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009; 106:20365 - 70; http://dx.doi.org/10.1073/pnas.0911580106; PMID: 19918065
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Gravenstein S, Upshaw CM, Hooton JW, Krause P, Drinka P, Bleackley RC. Granzyme B: a marker of risk for influenza in institutionalized older adults. Vaccine 2001; 19:3744 - 51; http://dx.doi.org/10.1016/S0264-410X(01)00087-1; PMID: 11395209
   PubMed Web of Science ®Google Scholar
• Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013; 19:1305 - 12; http://dx.doi.org/10.1038/nm.3350; PMID: 24056771
   PubMed Web of Science ®Google Scholar
• McElhaney JE. Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response. Expert Rev Vaccines 2009; 8:593 - 606; http://dx.doi.org/10.1586/erv.09.12; PMID: 19397416
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, Hager WD, Barry MB, Kleppinger A, Wang Y, Bleackley RC. Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009; 27:2418 - 25; http://dx.doi.org/10.1016/j.vaccine.2009.01.136; PMID: 19368783
   PubMed Web of Science ®Google Scholar
• Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010; 28:6145 - 51; http://dx.doi.org/10.1016/j.vaccine.2010.07.036; PMID: 20646987
   PubMed Web of Science ®Google Scholar
• Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, Flano E, Mejias A, Albrecht RA, Blankenship D, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. 2013; 5:176 176ra32
   PubMed Web of Science ®Google Scholar
• Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4⁺ T cells in immunity to viruses. Nat Rev Immunol 2012; 12:136 - 48; PMID: 22266691
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274 - 80; http://dx.doi.org/10.1038/nm.2612; PMID: 22286307
   PubMed Web of Science ®Google Scholar
• Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009; 106:3877 - 82; http://dx.doi.org/10.1073/pnas.0813390106; PMID: 19237568
   PubMed Web of Science ®Google Scholar
• Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respir Viruses 2011; 5:426 - 37; http://dx.doi.org/10.1111/j.1750-2659.2011.00256.x; PMID: 21668670
   PubMed Web of Science ®Google Scholar
• Kang KS, Lee N, Shin MS, Kim SD, Yu Y, Mohanty S, Belshe RB, Montgomery RR, Shaw AC, Kang I. An altered relationship of influenza vaccine-specific IgG responses with T cell immunity occurs with aging in humans. Clin Immunol 2013; 147:79 - 88; http://dx.doi.org/10.1016/j.clim.2013.02.022; PMID: 23578549
   PubMed Web of Science ®Google Scholar
• Hillaire ML, van Trierum SE, Kreijtz JH, Bodewes R, Geelhoed-Mieras MM, Nieuwkoop NJ, Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 2011; 92:2339 - 49; http://dx.doi.org/10.1099/vir.0.033076-0; PMID: 21653752
   PubMed Web of Science ®Google Scholar
• Hillaire M, Rimmelzwaan G, Kreijtz J.. Clearance of influenza virus infections by T cells: risk of collateral damage?. Curr Opin Virol. 2013; 3:4 430 - 7
   PubMed Web of Science ®Google Scholar
• Sun J, Braciale TJ. Role of T cell immunity in recovery from influenza virus infection. Curr Opin Virol. 2013; 3:4 425 - 9
   PubMed Web of Science ®Google Scholar
• Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 2013; 5:200 200ra114
   PubMed Web of Science ®Google Scholar
• Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011; 52:1 1 - 7
   PubMed Web of Science ®Google Scholar
• Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis. 2012; 55:1 19 - 25
   PubMed Web of Science ®Google Scholar
• Pleguezuelos O, Robinson S, Stoloff GA, Caparrós-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine 2012; 30:4655 - 60; http://dx.doi.org/10.1016/j.vaccine.2012.04.089; PMID: 22575166
   PubMed Web of Science ®Google Scholar
• Systems IT. Flunisyn, pan-influenza strain vaccine. Trends Immunol. 2011; 32:11 524 - 31
   PubMed Web of Science ®Google Scholar
• Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013; 13:238 - 50; http://dx.doi.org/10.1016/S1473-3099(12)70345-6; PMID: 23369412
   PubMed Web of Science ®Google Scholar
• Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, Gilbert SC. Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. Mol Ther 2014; 22:3 668 - 74
   PubMed Web of Science ®Google Scholar
• Gijzen K, Liu WM, Visontai I, Oftung F, van der Werf S, Korsvold GE, Pronk I, Aaberge IS, Tütto A, Jankovics I, et al. Standardization and validation of assays determining cellular immune responses against influenza. Vaccine 2010; 28:3416 - 22; http://dx.doi.org/10.1016/j.vaccine.2010.02.076; PMID: 20206285
   PubMed Web of Science ®Google Scholar
• Thomas PG, Keating R, Hulse-Post DJ, Doherty PC. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006; 12:48 - 54; http://dx.doi.org/10.3201/eid1201.051237; PMID: 16494717
   PubMed Web of Science ®Google Scholar
• Rose MA, Zielen S, Baumann U. Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines 2012; 11:595 - 607; http://dx.doi.org/10.1586/erv.12.31; PMID: 22827245
   PubMed Web of Science ®Google Scholar
• Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, Shimada S, Nanno M, Matsuoka Y, Ohwaki M, et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 2002; 168:6 2930 - 8
   PubMed Web of Science ®Google Scholar
• Taylor HP, Dimmock NJ. Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J Exp Med 1985; 161:198 - 209; http://dx.doi.org/10.1084/jem.161.1.198; PMID: 2981953
   PubMed Web of Science ®Google Scholar
• Mazanec MB, Coudret CL, Fletcher DR. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995; 69:1339 - 43; PMID: 7815518
   PubMed Web of Science ®Google Scholar
• Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM, CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685 - 96; http://dx.doi.org/10.1056/NEJMoa065368; PMID: 17301299
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36 - 44; http://dx.doi.org/10.1016/S1473-3099(11)70295-X; PMID: 22032844
   PubMed Web of Science ®Google Scholar
• Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine 2009; 27:1101 - 10; http://dx.doi.org/10.1016/j.vaccine.2008.11.093; PMID: 19095024
   PubMed Web of Science ®Google Scholar
• Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011; 204:845 - 53; http://dx.doi.org/10.1093/infdis/jir436; PMID: 21846636
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007; 25:5467 - 84; http://dx.doi.org/10.1016/j.vaccine.2006.12.001; PMID: 17227687
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148 - 58; http://dx.doi.org/10.1038/nri1777; PMID: 16491139
   PubMed Web of Science ®Google Scholar
• Weiner HL. The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol 2001; 2:671 - 2; http://dx.doi.org/10.1038/90604; PMID: 11477400
   PubMed Web of Science ®Google Scholar
• Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 2008; 38:114 - 26; http://dx.doi.org/10.1002/eji.200636959; PMID: 18081037
   PubMed Web of Science ®Google Scholar
• Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations. Expert Rev Vaccines 2011; 10:365 - 75; http://dx.doi.org/10.1586/erv.10.172; PMID: 21434804
   PubMed Web of Science ®Google Scholar
• Saluja V, Amorij JP, van Roosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, Frijlink HW. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS J 2010; 12:109 - 16; http://dx.doi.org/10.1208/s12248-009-9168-2; PMID: 20058113
   PubMed Web of Science ®Google Scholar
• Zhang J. Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines. Viruses 2012; 4:2711 - 35; http://dx.doi.org/10.3390/v4112711; PMID: 23202501
   PubMed Web of Science ®Google Scholar
• Peters W, Brandl JR, Lindbloom JD, Martinez CJ, Scallan CD, Trager GR, Tingley DW, Kabongo ML, Tucker SN. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans. Vaccine 2013; 31:1752 - 8; http://dx.doi.org/10.1016/j.vaccine.2013.01.023; PMID: 23357198
   PubMed Web of Science ®Google Scholar
• Park HJ, Ferko B, Byun YH, Song JH, Han GY, Roethl E, Egorov A, Muster T, Seong B, Kweon MN, et al. Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice. PLoS One 2012; 7:e39921; http://dx.doi.org/10.1371/journal.pone.0039921; PMID: 22761928
   PubMed Web of Science ®Google Scholar
• Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, et al. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One 2011; 6:e27953; http://dx.doi.org/10.1371/journal.pone.0027953; PMID: 22140491
   PubMed Web of Science ®Google Scholar
• Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, Park SH, Czerkinsky C, Kweon MN. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 2008; 105:1644 - 9; http://dx.doi.org/10.1073/pnas.0708684105; PMID: 18227512
   PubMed Web of Science ®Google Scholar
• Shen X, Söderholm J, Lin F, Kobinger G, Bello A, Gregg DA, Broderick KE, Sardesai NY. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model. Vaccine 2012; 30:6946 - 54; http://dx.doi.org/10.1016/j.vaccine.2012.02.071; PMID: 22406460
   PubMed Web of Science ®Google Scholar
• Barría MI, Garrido JL, Stein C, Scher E, Ge Y, Engel SM, Kraus TA, Banach D, Moran TM. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis 2013; 207:115 - 24; http://dx.doi.org/10.1093/infdis/jis641; PMID: 23087433
   PubMed Web of Science ®Google Scholar
• Ainai A, Tamura S, Suzuki T, van Riet E, Ito R, Odagiri T, Tashiro M, Kurata T, Hasegawa H. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Hum Vaccin Immunother 2013; 9:1962 - 70; http://dx.doi.org/10.4161/hv.25458; PMID: 23896606
   PubMed Web of Science ®Google Scholar
• Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP, Khan N, Li GM, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011; 12:786 - 95; http://dx.doi.org/10.1038/ni.2067; PMID: 21743478
   PubMed Web of Science ®Google Scholar
• Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10:116 - 25; http://dx.doi.org/10.1038/ni.1688; PMID: 19029902
   PubMed Web of Science ®Google Scholar
• Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev Vaccines 2012; 11:985 - 94; http://dx.doi.org/10.1586/erv.12.61; PMID: 23002979
   PubMed Web of Science ®Google Scholar
• Obermoser G, Presnell S, Domico K, Xu H, Wang Y, Anguiano E, Thompson-Snipes L, Ranganathan R, Zeitner B, Bjork A, et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013; 38:831 - 44; http://dx.doi.org/10.1016/j.immuni.2012.12.008; PMID: 23601689
   PubMed Web of Science ®Google Scholar
• Bodewes R, Rimmelzwaan GF, Osterhaus AD. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines 2010; 9:59 - 72; http://dx.doi.org/10.1586/erv.09.148; PMID: 20021306
   PubMed Web of Science ®Google Scholar
• Belser JA, Tumpey TM. H5N1 pathogenesis studies in mammalian models. Virus Res 2013; 178:168 - 85; http://dx.doi.org/10.1016/j.virusres.2013.02.003; PMID: 23458998
   PubMed Web of Science ®Google Scholar
• Tripp RA, Tompkins SM. Animal models for evaluation of influenza vaccines. Curr Top Microbiol Immunol 2009; 333:397 - 412; http://dx.doi.org/10.1007/978-3-540-92165-3_19; PMID: 19768416
   PubMedGoogle Scholar
• van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, Oxford J. Animal models in influenza vaccine testing. Expert Rev Vaccines 2008; 7:783 - 93; http://dx.doi.org/10.1586/14760584.7.6.783; PMID: 18665776
   PubMed Web of Science ®Google Scholar
• Bodewes R, Kreijtz JH, van Amerongen G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF, Kuiken T. Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation. Am J Pathol 2011; 179:30 - 6; http://dx.doi.org/10.1016/j.ajpath.2011.03.026; PMID: 21640972
   PubMed Web of Science ®Google Scholar
• Marois I, Cloutier A, Garneau É, Richter MV. Initial infectious dose dictates the innate, adaptive, and memory responses to influenza in the respiratory tract. J Leukoc Biol 2012; 92:107 - 21; http://dx.doi.org/10.1189/jlb.1011490; PMID: 22504848
   PubMed Web of Science ®Google Scholar
• Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, et al, Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261 - 73; http://dx.doi.org/10.1056/NEJMra0707279; PMID: 18199865
   PubMed Web of Science ®Google Scholar
• Korteweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol 2008; 172:1155 - 70; http://dx.doi.org/10.2353/ajpath.2008.070791; PMID: 18403604
   PubMed Web of Science ®Google Scholar
• Plotnicky H, Cyblat-Chanal D, Aubry JP, Derouet F, Klinguer-Hamour C, Beck A, Bonnefoy JY, Corvaïa N. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice. Virology 2003; 309:320 - 9; http://dx.doi.org/10.1016/S0042-6822(03)00072-2; PMID: 12758178
   PubMed Web of Science ®Google Scholar
• Tan AC, Deliyannis G, Bharadwaj M, Brown LE, Zeng W, Jackson DC. The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol 2013; 91:96 - 104; http://dx.doi.org/10.1038/icb.2012.54; PMID: 23146941
   PubMed Web of Science ®Google Scholar
• Martel CJ, Aasted B. Characterization of antibodies against ferret immunoglobulins, cytokines and CD markers. Vet Immunol Immunopathol 2009; 132:109 - 15; http://dx.doi.org/10.1016/j.vetimm.2009.05.011; PMID: 19505731
   PubMed Web of Science ®Google Scholar
• Rutigliano JA, Doherty PC, Franks J, Morris MY, Reynolds C, Thomas PG. Screening monoclonal antibodies for cross-reactivity in the ferret model of influenza infection. J Immunol Methods 2008; 336:71 - 7; http://dx.doi.org/10.1016/j.jim.2008.04.003; PMID: 18485358
   PubMed Web of Science ®Google Scholar
• Ochi A, Danesh A, Seneviratne C, Banner D, Devries ME, Rowe T, Xu L, Ran L, Czub M, Bosinger SE, et al. Cloning, expression and immunoassay detection of ferret IFN-gamma. Dev Comp Immunol 2008; 32:890 - 7; http://dx.doi.org/10.1016/j.dci.2007.12.008; PMID: 18262264
   PubMed Web of Science ®Google Scholar
• Pillet S, Kobasa D, Meunier I, Gray M, Laddy D, Weiner DB, von Messling V, Kobinger GP. Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine 2011; 29:6793 - 801; http://dx.doi.org/10.1016/j.vaccine.2010.12.059; PMID: 21211587
   PubMed Web of Science ®Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247 - 58; http://dx.doi.org/10.1038/nri2274; PMID: 18323851
   PubMed Web of Science ®Google Scholar
• Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, Ben-Yedidia T. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. J Clin Immunol 2012; 32:595 - 603; http://dx.doi.org/10.1007/s10875-011-9632-5; PMID: 22318394
   PubMed Web of Science ®Google Scholar
• Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28:2565 - 72; http://dx.doi.org/10.1016/j.vaccine.2010.01.029; PMID: 20117262
   PubMed Web of Science ®Google Scholar
• Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin-Williams R, Mant T, Nolan A, Zambon M, Ellis J, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009; 27:2506 - 12; http://dx.doi.org/10.1016/j.vaccine.2009.02.061; PMID: 19368793
   PubMed Web of Science ®Google Scholar
• Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina LP. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010; 5:e15559; http://dx.doi.org/10.1371/journal.pone.0015559; PMID: 21203523
   PubMed Web of Science ®Google Scholar
• Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158 - 66; http://dx.doi.org/10.1093/infdis/jis330; PMID: 22551811
   PubMed Web of Science ®Google Scholar
• Hubby B, Talarico T, Maughan M, Reap EA, Berglund P, Kamrud KI, Copp L, Lewis W, Cecil C, Norberg P, et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 2007; 25:8180 - 9; http://dx.doi.org/10.1016/j.vaccine.2007.09.038; PMID: 17961878
   PubMed Web of Science ®Google Scholar
• Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 2012; 30:5761 - 9; http://dx.doi.org/10.1016/j.vaccine.2012.06.086; PMID: 22796139
   PubMed Web of Science ®Google Scholar
• Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011; 29:4897 - 902; http://dx.doi.org/10.1016/j.vaccine.2011.05.001; PMID: 21596084
   PubMed Web of Science ®Google Scholar
• Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011; 29:5145 - 52; http://dx.doi.org/10.1016/j.vaccine.2011.05.041; PMID: 21624416
   PubMed Web of Science ®Google Scholar